When Boston Scientific’s cardiac monitor, the LUX-Dx ICM, started to become popular back in 2020, analysts said that it outperformed the rest of the products currently on the market. One of the companies that supposedly lost market share during this time was the US based Medical Device company, Abbott.

But now, Abbott has developed a rival cardiac monitoring product with a distinctive USP. They have created a device with a six-year battery life, even surpassing Medtronic’s LINQ II, which lasts four and a half years.

“Abbott has developed a rival cardiac monitoring product with a six-year battery life“

This will be especially helpful to doctors who are keeping an eye on patients receiving treatment post cardiac ablation procedure. These individuals have a greater chance of experiencing irregular or abnormal heart beats.

Abbott’s Chief Medical officer for their cardiac rhythm management division, Leonard Ganz, described how this product meets a currently unmet need. Although cardiac monitors have been used for remote care before, they have “lacked the longevity needed to monitor them long term.” He said that “Abbott’s Assert-IQ ICM offers physicians a connected health device that will help them provide the best care while making more accurate and informed treatment decisions.”

An adapted product is also available for briefer observation periods, lasting just three years. Every 20 seconds, the monitors assess cardiac rhythms, and send this data to a medical professional via Bluetooth. They were developed specifically to identify well- hidden cardiac rhythm anomalies.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.